AMARIN CORP PLC\UK Cost of Revenue
AMARIN CORP PLC\UK (AMRN) reported Cost of Revenue of $22.24 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-04.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2022-05-04
- AMARIN CORP PLC\UK cost of goods and services sold for the quarter ending 2022-03-31 was $22.24M, a 21.49% decline year-over-year.
- AMARIN CORP PLC\UK cost of goods and services sold for the quarter ending 2021-12-31 was $30.64M, a 11.89% decline year-over-year.
- AMARIN CORP PLC\UK cost of goods and services sold for the quarter ending 2021-09-30 was $30.21M, a 8.65% decline year-over-year.
- AMARIN CORP PLC\UK cost of goods and services sold for the quarter ending 2021-06-30 was $32.16M, a 11.66% increase year-over-year.
- AMARIN CORP PLC\UK cost of goods and services sold for fiscal 2021 was $121.33M, a 7.70% decline from fiscal 2020.
- AMARIN CORP PLC\UK cost of goods and services sold for fiscal 2020 was $131.44M, a 36.89% increase from fiscal 2019.
- AMARIN CORP PLC\UK cost of goods and services sold for fiscal 2019 was $96.02M, a 76.04% increase from fiscal 2018.
- AMARIN CORP PLC\UK cost of goods and services sold for fiscal 2018 was $54.54M, a 21.34% increase from fiscal 2017.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2022-03-31 | $22.24M 10-Q · filed 2022-05-04 | $52.87M derived: sum of 2 quarters · filed 2022-05-04 | $83.08M derived: sum of 3 quarters · filed 2022-05-04 | $115.24M derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-12-31 | $30.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $60.85M derived: sum of 2 quarters · filed 2022-03-01 | $93.00M derived: sum of 3 quarters · filed 2022-03-01 | $121.33M 10-K · filed 2022-03-01 |
| 2021-09-30 | $30.21M 10-Q · filed 2021-11-03 | $62.37M derived: sum of 2 quarters · filed 2021-11-03 | $90.69M 10-Q · filed 2021-11-03 | $125.46M derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-06-30 | $32.16M 10-Q · filed 2021-08-05 | $60.48M 10-Q · filed 2021-08-05 | $95.25M derived: sum of 3 quarters · filed 2022-05-04 | $128.32M derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-03-31 | $28.33M 10-Q · filed 2022-05-04 | $63.09M derived: sum of 2 quarters · filed 2022-05-04 | $96.17M derived: sum of 3 quarters · filed 2022-05-04 | $124.96M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $34.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $67.84M derived: sum of 2 quarters · filed 2022-03-01 | $96.64M derived: sum of 3 quarters · filed 2022-03-01 | $131.44M 10-K · filed 2022-03-01 |
| 2020-09-30 | $33.07M 10-Q · filed 2021-11-03 | $61.87M derived: sum of 2 quarters · filed 2021-11-03 | $96.68M 10-Q · filed 2021-11-03 | $127.34M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $28.80M 10-Q · filed 2021-08-05 | $63.60M 10-Q · filed 2021-08-05 | $94.27M derived: sum of 3 quarters · filed 2022-03-01 | $119.71M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $34.81M 10-Q · filed 2021-04-29 | $65.47M derived: sum of 2 quarters · filed 2022-03-01 | $90.92M derived: sum of 3 quarters · filed 2022-03-01 | $113.69M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $30.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $56.11M derived: sum of 2 quarters · filed 2022-03-01 | $78.88M derived: sum of 3 quarters · filed 2022-03-01 | $96.02M 10-K · filed 2022-03-01 |
| 2019-09-30 | $25.44M 10-Q · filed 2020-11-05 | $48.21M derived: sum of 2 quarters · filed 2020-11-05 | $65.35M 10-Q · filed 2020-11-05 | $82.86M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $22.77M 10-Q · filed 2020-08-04 | $39.91M 10-Q · filed 2020-08-04 | $57.42M derived: sum of 3 quarters · filed 2021-02-25 | $70.96M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $17.14M 10-Q · filed 2020-04-30 | $34.65M derived: sum of 2 quarters · filed 2021-02-25 | $48.19M derived: sum of 3 quarters · filed 2021-02-25 | $61.03M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $17.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $31.05M derived: sum of 2 quarters · filed 2021-02-25 | $43.90M derived: sum of 3 quarters · filed 2021-02-25 | $54.54M 10-K · filed 2021-02-25 |
| 2018-09-30 | $13.54M 10-Q · filed 2019-11-05 | $26.39M derived: sum of 2 quarters · filed 2019-11-05 | $37.03M 10-Q · filed 2019-11-05 | $50.47M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $12.85M 10-Q · filed 2019-07-31 | $23.49M 10-Q · filed 2019-07-31 | $36.93M derived: sum of 3 quarters · filed 2020-02-25 | $48.85M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $10.65M 10-Q · filed 2019-05-01 | $24.08M derived: sum of 2 quarters · filed 2020-02-25 | $36.00M derived: sum of 3 quarters · filed 2020-02-25 | $47.40M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $13.43M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $25.35M derived: sum of 2 quarters · filed 2020-02-25 | $36.75M derived: sum of 3 quarters · filed 2020-02-25 | $44.95M 10-K · filed 2020-02-25 |
| 2017-09-30 | $11.92M 10-Q · filed 2018-11-01 | $23.32M derived: sum of 2 quarters · filed 2018-11-01 | $31.52M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $11.40M 10-Q · filed 2018-08-01 | $19.60M 10-Q · filed 2018-08-01 | ||
| 2016-12-31 | $34.36M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |